Nexstim Plc in Technology Licensing Discussions with a Leading California Based Academic Institution


Company announcement, Helsinki 2 October 2019 at 9.00 AM (EEST)

Nexstim Plc in Technology Licensing Discussions with a Leading California Based Academic Institution

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") – the company developing and marketing a unique brain stimulation technology for personalized treatment of major depressive disorder (MDD),  announces that it is in discussions with a leading California based academic institution regarding the licensing of their technology to treat patients with severe depression, who are hospitalised and may have suicidal ideation.

This project could open an exciting new TMS market for treatment resistant depression (TRD), which is distinct from the current market.

Martin Jamieson, Chairman and CEO of Nexstim, commented: “The combination of this technology and Nexstim’s SmartFocus® navigation promises to provide an effective new therapeutic option for this highly treatment resistant population. We believe that Nexstim’s unique navigation precision is crucial in delivering improved treatment outcomes. The market opportunity is also very attractive, particularly in the USA, where approximately 650 psychiatric hospitals treat an estimated 160,000 patients annually.”

There can be no assurance that the discussions will result in a licensing agreement. The Company has not set a timetable for the discussions, and it does not intend to comment further unless the Company has otherwise determined that further disclosure is appropriate or required by law.

Further information is available on the website, or by contacting:

Martin Jamieson, Chairman and CEO
+44 771 516 3942

Sisu Partners Oy (Certified Adviser)
Jussi Majamaa
+ 358 40 842 4479

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit


About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire


Active Biotech AB (publ) (ticker: ACTI) meddelade idag statusuppdateringar av sina helägda projekt tasquinimod och laquinimod, liksom samarbetsprojektet naptumomab, utvecklat tillsammans med NeoTX Therapeutics. Investerare, analytiker och media är inbjudna till dagens virtuella kapitalmarknadsdag där den aktuella statusen och framtida utvecklingen av företagets kliniska portfölj och dess framtida strategi kommer att belysas. För ytterligare information, vänligen kontakta: Helén Tuvesson, VD, 046 19 21 56, Hans Kolam, CFO, 046 19 20 44, Denna information är sådan information som Active Biotech är skyldig att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 24 november 2020 kl. 08.00. Om Active Biotech Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) är ett bioteknikföretag som använder sin omfattande kompetensbas och projektportf

Ahold Delhaize share buyback update24.11.2020 08:00:00 CETPress release

Zaandam, the Netherlands, November 24, 2020 – Ahold Delhaize has repurchased 1,071,128 of Ahold Delhaize common shares in the period from November 16, 2020 up to and including November 20, 2020. The shares were repurchased at an average price of €23.39 per share for a total consideration of € 25.1 million. These repurchases were made as part of the €1 billion share buyback program announced on December 4, 2019. The total number of shares repurchased under this program to date is 41,012,539 common shares for a total consideration of € 943 million. Download the share buyback transactions excel sheet for detailed individual transaction information from This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.


Active Biotech AB (publ) (ticker: ACTI) today announced updates of its fully owned projects tasquinimod and laquinimod, as well the project naptumomab, developed in partnership with NeoTX Therapeutics. Investors, analysts and media are invited to today’s virtual Capital Markets Day where the current status and future developments of the company’s clinical portfolio and its future strategy will be highlighted. For further information, please contact: Helén Tuvesson, CEO, +46 46 19 21 56, Hans Kolam, CFO, +46 46 19 20 44, Active Biotech is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation. This information was provided to the media, through the agency of the contact persons set out above, for publication November 24, 2020 at 08.00 CET. About Active Biotech Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge

10kW+ Laser Cutting Machine Made a Sales Record of 260 Sets, Bodor Laser Constantly Surprises the Market24.11.2020 07:42:54 CETPress release

SHANDONG, China, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The spring of 2020 is different. A sudden epidemic has stopped us from all kinds of progress. The world is shrouded in the haze of the epidemic, and the COVID-19 epidemic has become a matter of concern to everyone. There is no doubt that the outbreak of this epidemic has brought a great blow to the world economy. In this context, “high efficiency” has become the overall demand of manufacturing and processing in several major industries such as heavy machinery, urban rail transit, high-speed rail and new energy etc. With its excellent performance, 10kW+ laser cutting machine has gradually become the darling of the market and has been adopted by the majority of metal processing enterprises. As one of the fastest-growing companies in the laser industry, Bodor Laser has also taken part in this activity. Bodor Laser's 10kW+ products have become a representative of new productivity in the field of laser cutting by virtue of wider and deeper

Klövern signs two new rental contracts in Copenhagen24.11.2020 07:30:00 CETPress release

Klövern has signed a contract with Parfums Christian Dior for 973 sq.m. office space and a contract with Politiforbundet for 1,946 sq.m. office space in the so-called Codan-house on Gammel Kongevej in Copenhagen. Moving-in is estimated to be on 1 March 2021 and 1 June 2021, respectively. ”It is with great pleasure that we welcome our new tenants to the Codan-house where we have had a very great interest in rentals after our acquisition of the property. The Copenhagen rental market is strong and these lettings are steps in our plan to transform the property from a single-tenant property to an attractive modern multi-let property”, says Andreas Lange, Head of Klövern’s business unit Copenhagen. Klövern AB (publ) For additional information, please contact: Rutger Arnhult, CEO, +46 (0)70-458 24 70, Lars Norrby, IR, +46 (0)76-777 38 00, Klövern is a real estate company committed to working closely with customers to offer them attractive premi

Klövern tecknar två nya hyresavtal i Köpenhamn24.11.2020 07:30:00 CETPressemelding

Klövern har tecknat ett avtal med Parfums Christian Dior avseende 973 kvm kontorsyta och ett avtal med Politiforbundet avseende 1 946 kvm kontorsyta i det så kallade Codan-huset på Gammel Kongevej i Köpenhamn. Inflyttning beräknas ske den 1 mars 2021 respektive 1 juni 2021. ”Det är med stor glädje vi välkomnar våra nya hyresgäster till Codan-huset där vi haft ett mycket stort intresse för förhyrningar efter vårt förvärv av fastigheten. Köpenhamns hyresmarknad är stark och dessa uthyrningar är ett led i vår plan att ställa om fastigheten från en single-tenant-fastighet till en attraktiv modern mutli-let-fastighet”, säger Andreas Lange, Klöverns affärsenhetschef i Köpenhamn. Klövern AB (publ) För ytterligare information, vänligen kontakta: Rutger Arnhult, VD, 070-458 24 70, Lars Norrby, IR, 076-777 38 00, Klövern är ett fastighetsbolag som med närhet och engagemang erbjuder attraktiva lokaler i tillväxtregioner. Klövern är noterad på Nasda